Whole-body diffusion-weighted magnetic resonance imaging for Peritoneal Carcinomatosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
CHU de Québec, Quebec City, Canada
Peritoneal Carcinomatosis+8 More
Whole-body diffusion-weighted magnetic resonance imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.

Eligible Conditions

  • Peritoneal Carcinomatosis
  • Pancreas Cancer, Duct Cell Adenocarcinoma
  • Adenocarcinoma
  • Neoplasm Metastasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Peritoneal Carcinomatosis

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 30 months

24 months
Peritoneal findings
Unexpected abortion
30 months
Early distant recurrence

Trial Safety

Safety Progress

1 of 3

Other trials for Peritoneal Carcinomatosis

Trial Design

1 Treatment Group

DWI-MRI
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Whole-body diffusion-weighted magnetic resonance imaging · No Placebo Group · N/A

DWI-MRI
DiagnosticTest
Experimental Group · 1 Intervention: Whole-body diffusion-weighted magnetic resonance imaging · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months
Closest Location: CHU de Québec · Quebec City, Canada
Photo of quebec 1Photo of quebec 2Photo of quebec 3
2016First Recorded Clinical Trial
1 TrialsResearching Peritoneal Carcinomatosis
12 CompletedClinical Trials

Who is running the clinical trial?

Laval UniversityLead Sponsor
381 Previous Clinical Trials
154,146 Total Patients Enrolled
Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a confirmed diagnosis of pancreatic ductal adenocarcinoma.
The CA 19-9 level is ≥ 400 U/mL with normal bilirubin level (< 40).
Patient fit for pancreatic resection (ECOG 0 or 1).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References